Vera Therapeutics, Inc. Class A Common Stock
VERA US92337R1014
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 132% | -31% | -16% | 171% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Enright Patrick G |
22.35 USD |
13,536 Bought |
302,553 USD |
23/06/2025 | 24/06/2025 |
| Enright Patrick G |
22.35 USD |
27,071 Bought |
605,083 USD |
23/06/2025 | 24/06/2025 |
| Enright Patrick G |
20.87 USD |
69,798 Bought |
1,456,566 USD |
23/06/2025 | 23/06/2025 |
| Enright Patrick G |
20.87 USD |
139,595 Bought |
2,913,110 USD |
23/06/2025 | 23/06/2025 |
| Fordyce Marshall CEO |
28.32 USD |
1,100 Sold |
31,150 USD |
21/02/2025 | 26/02/2025 |
| Fordyce Marshall CEO |
27.55 USD |
7,975 Sold |
219,732 USD |
21/02/2025 | 26/02/2025 |
| Fordyce Marshall CEO |
27.89 USD |
10,613 Sold |
296,032 USD |
21/02/2025 | 21/02/2025 |
| Fordyce Marshall CEO |
42.03 USD |
5,650 Sold |
237,489 USD |
08/01/2025 | 08/01/2025 |
| Fordyce Marshall CEO |
42.00 USD |
1,875 Sold |
78,750 USD |
08/01/2025 | 08/01/2025 |
| Fordyce Marshall CEO |
41.53 USD |
9,975 Sold |
414,297 USD |
08/01/2025 | 08/01/2025 |